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S_nmry In order to describe renal involvement in aggressive non-Hodgkin's lymphomas (NHLs) and its
prognostic significance, we reviewed the outcome of 48 patients with renal involvement treated with the
LNH-84 or LNH-87 regimen. Histology was diffuse large cell in 29 (60%) patients; immmunoblastic, diffuse
mixed cell and lymphoblastic in four each; follicular large cell, diffuse small cleaved cell and diffuse small
non-cleaved cell in one each; and unclassified in four. Ann Arbor stage was IV in 44 patients, and IE or IIE in
four. Tumour mass > 10cm, performance status (ECOG scale) >2 and increased LDH level were present in
69%, 20% and 76% of patients respectively. Fifteen patients (31%) had multiple intraparenchymal nodules,
14 (29%) had direct spread into the kidney from a perirenal mass, ten (21%) had a single intraparenchymal
nodule and nine (19%) had diffuse infiltration. Twenty-one patients (43%) presented with bilateral lesions.
Three patients (6%) presented with acute renal failure. Ten other patients (21%) had serum creatinine
>120 zmoll-'. In 12 of these 13 patients renal function was restored with chemotherapy. Twenty-eight
patients (57%) achieved complete remission. Estimated 4 year disease-free survival was 39%. Disease-free
survival and actuarial survival at 4 years were estimated to be 58% respectively. Two renal parameters had
adverse prognostic sig i for survival: renal hilum involvement (P = 0.02) and diffuse renal infiltration
(P = 0.01). A Cox model identified only two independent prognostic factors for survival, namely performance
status >2 and tumour size > 10 cm. We conclude that alteration in renal function occurs in 27% of patients
with renal involvement. Systemic chemotherapy improves renal function rapidly. Long-term outcome is similar
to that expected in NHL patients presenting with the same prognostic factors.
In clinical studies, the prevalence of renal involvement in
patients with non-Hodgkin's lymphoma (NHL) ranges from
2.4% to 14% (Richmond et al., 1962; Strauss et al., 1983;
Geffen et al., 1985; Richards et al., 1990). This low incidence
contrasts with the high prevalence (nearly 50%) of renal
involvement found at autopsy (Wentzell & Berkheise, 1955;
Martinez-Maldonado & Ramirez de Arellano, 1966; Lalli,
1969; Kandel et al., 1987; Richards et al., 1990). Until the
introduction of computerised tomography (CT), renal
involvement was often found late in the clinical course of
NHL patients. Systematic CT increased the early detection of
renal lymphomatous involvement.
Intensive combination chemotherapy regimens in patients
with aggressive NHL have been associated with complete
response and 5 year survival rates of 75% and 60% respec-
tively (Coiffier et al., 1989). Most NHLs with renal involve-
ment are aggressive (Richards et al., 1990). Previous reviews
of renal lymphomas were retrospective studies that included
patients who received various regimens (Geffen et al., 1985;
Richards et al., 1990). The results of intensive combination
chemotherapy regimens in patients with renal lymphomatous
involvement have not been specifically analysed. In addition,
prognostic factors identified in aggressive malignant lym-
phomas have not yet been assessed in this group of patients.
For these reasons, we evaluated the renal symptoms, the
prognostic factors and the outcome in 48 patients with
aggressive lymphoma and renal involvement who were
enrolled in the LNH-84 or LNH-87 regimen.
included in the prospective multicentre LNH-84 and LNH-87
protocols for aggressive lymphomas. Treatment modalities,
detailed data and results for the 737 LNH-84 patients have
been described previously (Coiffier et al., 1989). Renal
involvement was found in 80 of the 2,727 patients (3%).
Eligibility criteria for this present study were: (i) histo-
logically proven renal involvement or (ii) computerised
tomography scan showing renal involvement available for
review. Forty-eight of these 80 patients fulfilled at least one
of these criteria. Thirty-two patients were excluded from this
study (nine patients had only ultrasonic examination and Cr
scan showing renal involvement was not available for retro-
spective review in 23 patients).
Diagnosis ofrenal involvement
Diagnosis of renal or perirenal involvement was based either
on a combination ofcomputerised tomographic (Cr) scan and
ultrasonic criteria (26 patients) or on histological examina-
tion (22 patients). Histological procedures were percutaneous
biopsy of renal or perirenal mass (four patients), open renal
biopsy (six patients) or nephrectomy (12 patients). All
patients had at least one of the following lesions: single or
multiple nodules, diffuse renal infiltration with enlargement
of the kidney or direct spread into the renal substance from a
perirenal mass. Hydronephrosis accompanied by a retroperi-
toneal mass without direct invasion of the kidney was ex-
cluded.
Patients and metbods
Between October 1984 and November 1990, 737 and 1,990
adult patients with aggressive NHL were respectively
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Staging and management oftymphoma
The diagnosis of lymphoma was based on review of biopsy
material by the staff of the pathologists of the 'Groupe
d'Etude des Lymphomes de l'Adulte' (GELA) and classified
according to the International Working Formulation (The
Non-Hodgkin Lymphoma Pathologic Classification Project,
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1982). Immunochemistry analyses on frozen section were
performed in 30 patients. All patients had a complete
physical examination, thoracic and abdominal CT scan and
bone marrow trephine biopsy. Performance status was
graded using the Eastern Cooperative Oncology Group
(ECOG) scale. Disease was staged according to the Ann
Arbor system (Carbone et al., 1971). The lactic acid dehydro-
genase (LDH) level was known for all patients but one. Tests
for human immunodeficiency virus were negative in all
patients. Renal impairment was defined by serum creatinine
level > 120 mol I -'.
We applied two prognostic models to our patients: the
LNH-84 prognostic index (Coiflier et al., 1991) and the
international prognostic index (Shipp et al., 1992). Coiffier et
al. (1991) identified three prognostic subgroups, taking the
four following adverse prognostic factors into account: high
LDH level, size of the largest mass > 10 cm, > 2 extranodal
sites of disease and Ann Arbor stage III or IV. More
recently, Shipp et al. (1993) described an international prog-
nostic index that takes five adverse prognostic factors into
account, namely age >60, > 2 extranodal sites of disease,
performance status 2 or more, Ann Arbor stage III or IV,
increased LDH level. Low-risk patients have no or one
adverse prognostic factor. Low-intemediate risk patients
have two adverse prognostic factors. High-intermediate risk
patients have three adverse prognostic factors. High-risk
patients have four or five adverse prognostic factors.
Treatment
Fourteen patients were entered on the LNH-84 protocol
(Coiffier et al., 1989). The induction phase included four
courses of ACVB (doxorubicin 75mgm2 on day 1, cy-
clophosphamide 1,200mgm-2 on day 1, vindesine 2mgm 2
on days I and 5, bleomycin 1Omg on days 1 and 5, pred-
nisolone 60 mg m 2 on days 1-5) every 2-3 weeks and four
doses of intrathecal methotrexate 15 mg. Consolidation
therapy consisted of sequential courses including high-dose
methotrexate, ifosfamide plus etoposide, L-asparagnas, and
cytarabine followed by a randomised late intensification. Late
intensification did not influence survival or response rate.
Thirty-four patients were included in the multicentre LNH-
87 protocol (Gisselbrecht et al., 1991). Briefly, the goals of
the LNH-87 protocol were to compare the LNH-84 protocol
with another chemotherapy protocol in patients aged less
than 69 years and stratified in subgroups according to age
and adverse prognostic factors, and to assess the impact of
anthracycline on survival in patients older than 69 years.
More precisely, 12 patients received the same regimen as
the LNH-84 protocol. Three patients aged <55 years with
high-risk NHL received four courses of ACVB and under-
went an autologous bone marrow transplantation during first
complete remission (CR). Eleven patients aged > 55 years
received two courses of ACVB, alternated with two courses
of VIM3 (mitoxantrone 10 mg m2 on day 1, ifosfamide
1gm on days 1-3, mitaguazone 300mgm 2 on days 1
and 5, teniposide 100 mg m2 on days 1 and 5, methylpred-
nisolone 60 mgm-2 on days 1-5, methotrexate 1.5 gm-2 on
day 14 followed by rescue with folinic acid). Patients who
achieved a CR then received consolidation chemotherapy
with mitoxantrone, etoposide, ifosfamide, adriamycin, cyclo-
phosphamide, vindesinse and methotrexate for 4 months
(Bosly et al., 1993). Four patients aged >69 years received
six courses of a CVP regimen (cyclophosphamide 750 mg m-2
on day 1, teniposide 75 mg m-2 on day 1, methylpred-
nisolone 40 mg m-2 on days 1-3). Four other patients aged
>69 years received the same regimen with pirarubicine
45 mg m-2 on day 1 in addition. Interim analyses showed no
difference in survival between treatment arms in each sub-
group of patients of the LNH-87 protocol (Gisselbrecht et
al., 1991).
No dose adjustment was made for haematological toxicity,
but chemotherapy was delayed until the neutrophil count was
greater than 1,000 x I0'1' and platelet count greater than
100,O x lO91-'.
Assessment ofresponse
Response to treatment was assessed at the completion of
induction therapy. Tumour response was evaluated as com-
plete or partial according to standard guideines (Coiffier et
al., 1989). Disappearance of all clinical and radiological
evidence of previously known disease defined complete re-
sponse of the renal lymphomatous involvement. Patients with
persstent radiographic abnormalities at sites of previously
bulky tumours were deemed to have a complete response
with persisting residual mass if the reduction in tumour size
was greater than 50% and if lesions remained unchanged for
at least 2 months.
Haematological and infectious toxicities were graded
according to the World Health Organization recomma-
tions for grading of acute or subacute toxicity.
Statistical methods
The data were analysed using standard statistical methods
including chi-square or Yates chi-square tests, and Student's
t-test (Armitage, 1971). Survival curves were plotted accord-
ing to the Kaplan-Meier method and compared with the
log-rank test (ManteL 1966). Initial renal characteristics
identified by the univariate analysis were included in a pro-
portional hazards regression analysis of survival with the
stepwise selection (Cox, 1982). These analyses were per-
formed using the Statistical Application System (SAS) soft-
ware (SAS Institute, Cary, NC, USA).
Rets
The main initial characteristics of the 48 patients are shown
in Table I. Age ranged between 15 and 79 years (median 57
years). Twenty-five patients were male, and 23 were
female.
Characteristics ofrenal involvement
Renal symptoms revealed lymphoma in only 15 patients
(31%). The clinical characteristics of renal involvement in the
48 patients are shown in Table HI. Fifteen patients (31%) had
multiple intraparenchymal nodules, 14 (29%) had direct
spread into the renal substance from a perirenal mass, ten
(21%) had a single intraparenchymal nodule and nine (19%)
had diffuse infiltration with enlargement of the kidney. Renal
involvement was bilateral in 21 patients (43%). Involvement
of the perinephric space with thickening of Gerota's fascia
was found in 22 patients. Renal hilum and adrnals were
involved in 17 and six patients respectively. Adrenal involve-
ment was bilateral in four of the six patients. Bilateral renal
involvement was more frequent, and lomboaortic adeno-
pathies were less frequent, in patients with multiple nodules
than in other patients. Patients with diffuse infiltration or
perirenal mass had more renal hilum involvement than
patients with intraparenchymal nodules (P<0.05, Table
II).
The creatinine level was normal (<120pmoll-') in 35
patients. Thirteen patients had serum creatinine level
> 120jLmol I-': ten had mild renal impairment
(<270jimol 1-') and three had marked renal impairment
(>600Pmoll1'). These three patients had diffuse bilateral
infiltration.
Other clinicalfindings
Haematological findings are shown in Tables I and III.
Histology was diffuse large-cell lymphoma (G) in 60% of
patients. Phenotype was T in four patients, B in 23 patients,
undetermined inthree patients, and unknown inthe remain-
ing 18 patients. Ann Arbor stage was IV in 44 patients
(92%). Thirty-one patients (65%) had B symptoms. Medi-
astinum was bulky in 13 (27%) patients. Six patients had
only nodal disease besides their renal involvement, and 42156 P. MOREL et al.
patients had at least one other extranodal site (bone marrow,
15 patients; GI tract, 13 patients; liver, 11 patients; pleura, 11
patients; lung, eight patients; CNS, six patients; bone, six
patients; pancreas, four patients; head and neck, three
patients; skin, three patients; orbit, two patients; testis, one
Tabe I Initial characteristics of the 48 patients with lymphomatous
involvement of the kidney
Patients with
lymphomatous Other
involvement of LNH-84-treated
the kidney patients
Total number of patients 48 737
Age (years)
<50 24 (30%) 510,
50-70 26 (54%) 45%
>70 8 (16%) 4%
Histology (working formulation)
Follicular large cell 1 (2%) 4%
Diffuse small cleaved cell 1 (2%) 2%
Diffuse mixed 4 (8.5%) 17%
Diffuse large cell 29 (60%) 42%
Immunoblastic 4 (8.5%) 18%
Small non-cleaved 4 (8.5%) 4%
Lymphoblastic 1 (2%) 5%
Others 4 (8.5%) 8%
Bone marrow involvement
Yes 15 (31%) 23%
No 32 (67%) 77%
Unknown 1 (2%)
Ann Arbor stage
IE and IIE 4 (8%) 36%
IV 44 (92%) 49%
Performance status (ECOG)
0 or 1 28 (58%) 74%
,-2 20 (42%) 26%
Tumoral mass
< 10cm 14 (29%) 59%
l0cm 33 (69%) 41%
Unknown 1 (2%)
LDH level
>normal 30 (62%) 36%
normal 17 (36%) 64%
Unknown 1 (2%)
patient; ovary, one patient; thyroid, one patient; muscle, one
patient; diaphragm, one patient). Ten patients had a perfor-
mance status >2 and 36 patients (76%) had an increased
LDH level. No difference in haematological findings was
found between each renal lesion except for performance
status. Patients with diffuse infiltration or perirenal mass had
impaired performance status > 2 more frequently than
patients with intraparenchymal nodules (P<0.05, Table
III).
Clinical course
Eighteen patients (36%) achieved complete remission without
persisting residual mass. Ten patients (21%) with partial
response >50% were considered as complete responders
with persisting residual mass. Five other patients (11%)
achieved a response > 50%. Two patients had stable disease,
and 13 have died during treatment. Tumoral response was
comparable in kidney and elsewhere in the 38 evaluable
patients. The seven patients with partial response or stable
disease died from disease progression.
Two of the 28 complete responders died without evidence
of progressive disease at 3 and 4 months after CR achieve-
ment (sudden death, one patient; probable pulmonary throm-
boembolism, one patient). Ten of the 28 complete responders
relapsed 3-40 months after CR achievement. Estimated 4
year disease-free survival was 58±9%. The kidney was
involved at relapse in four patients. Three patients died
shortly after relapse. Five patients were alive with relapse and
two patients were alive in second partial response at the
closing date.
So far 25 patients have died. With a median follow-up of
12 months, actuarial overall survival was estimated to be
46 ± 7% at 48 months (Figure 1).
Toxicity
Forty of our 48 patients received their first chemotherapy
cycle without dosage modification. Only one of the three
patients with marked renal impairment had dose reduction of
chemotherapy. His renal function could not be restored and
he died. The two other patients received full-dose chemo-
therapy and their renal function was restored. In ten other
patients with initial renal impairment renal function was
restored as asessed by their serum blood urea nitrogen (BUN)
and creatinine levels at the end of the induction mgimen.
Table I Characteristics of lymphomatous involvement of the kidney
Total number Single Multiple Diffuse Perirenal
ofpatients nodule nodules infiltration mass
Total no. of patients 48 10 15 9 14
Bilateral infiltration
Yes 21 1 14 3 3
No 27 9 1 6 11
Perinephric space
Involved 22 3 0 6 13
Normal 23 6 14 2 1
Unknown 3 1 1 1 0
Renal hilum involvement
Yes 17 2 1 5 9
No 22 6 11 3 2
Unknown 9 2 3 1 3
Para-aortic adenopathies
Yes 33 8 6 6 13
No 15 2 9 3 1
Mesenteric adenopathies
Yes 19 3 5 3 8
No 26 7 9 6 4
Unknown 3 0 1 0 2
Creatinine level (pLmol -')
>120 13 1 4 3 5
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Table M Haematological characteristics of lymphoma patients with renal involvement
Total number Single Multiple Diffuse Perirenal
of patients nodile nodules infiltration mass
Total no. of patients 48 10 15 9 14
Age (years)
>55 21 3 8 4 6
)55 27 7 7 5 8
Histology
Diffuse large cell 29 5 12 4 8
Lymphoblastic 4 0 2 1 1
Others 15 5 1 4 5
Ann Arbor stage
IE-IIE 4 0 0 1 3
IV 44 10 15 8 11
Performance status (ECOG)
0 or 1 28 8 11 2 7
2 10 2 2 3 3
3 or4 10 0 2 4 4
Tumoral mass (cm)
.10 33 6 8 8 11
<10 14 3 7 1 3
Unknown 1 1 0 0 0
LDH level
normal 16 5 4 1 6
>normal 31 4 1 1 8 8
Unknown 1 1 0 0 0
Bone marrow involvement
Yes 15 2 4 4 5
No 32 7 11 5 9
Unknown 1 1 0 0 0
10,01- Total 48 Death
80-
. 60-
-
40-
20-
0 10 20
Month
s 25 Renal parameters associated with a high CR rate were
(Table IV) normal perinephric space (P = 0.01), multiple
nodular involvement of the kidney (P = 0.02) and normal
kidney hilum (P = 0.02).
Two renal parameters had adverse prognostic significace
for survival: renal hilum involvement (P = 0.02) and diffuse
renal infiltration (P = 0.01). Only three other prognostic fac-
tors were indicators of long survivaL, namely performance
status 0 or 1 (P = 0.001), normal LDH level (P = 0.02) and
diffuse large-cell histological subtype (P = 0.03). A Cox
model identified only two independent prognostic factors for 40 50 survival, namely performance status 2 or more and tumour
size >10 cm.
Fugwe I Overall survival of the 48 patients with non-Hodgkin's
lymphoma and renal involvement included in the LNH-84 or
LNH-87 protocol.
Acute renal insufficiency developed in five of the 35
patients with initial serum creatinine level <120p1moll-'.
The mechanism was known in only three patients: septic
haemolysis in one patient, drug-induced toxicity in one
patient and lethal acute tumour lysis in one patient Long-
term follow-up showed mild renal impairment in two patients
42 and 12 months after CR achievement. Pyelocalyceal dila-
tion and retraction of renal contour was observed on CT
scan in one patient each.
The pattern of other toxicities was similar to that expected
in a population of patients in the LNH-84 study with similar
age and performance status distribution. It was not
influenced by impairment of renal function at diagnosis.
Prognosticfactors
The LNH-84 prognostic index identified a subgroup of 40
high-risk patients and a subgroup of eight intermediate-risk
patients. International prognostic index identified a subgroup
of two low-risk patients, seven low- to intermediate-risk
patients, 19 high- to intermediate-risk patients and 20 high-
risk patients.
Our report demonstrates that a high complete response rate
and 4 year estimated survival rate can be achieved in aggres-
sive NHL with renal involvement with the LNH-84 or LNH-
87 regimen.
Distribution of histological subtypes of patients with lym-
phomatous involvement of the kidney was not significantly
different from that found in all patients enrolled in the
LNH-84 protocol (Coiffier et al., 1989). Our study excluded
low-grade NHL. However, only 7% of NHLs with renal
involvement are low-grade NHL (Glicklich et al., 1986;
Richards et al., 1990).
In 26 patients, renal involvement was diagnosed on CT
scan only. Radiological criteria are sufficient to diagnose a
renal lymphomatous involvement (Richards et al., 1990). CT
scan usually reveals a homogeneous mass that shares the
density of soft tissues, with a minimal enhancement after
injection (Heiken et al., 1983). Incidences of renal involve-
ment subtypes in our patients semed somewhat different
from those of previous reports (Richmond et al., 1962; Jafri
et al., 1982; Heiken et al., 1983). However, these studies
included only a small number of patients and the differences
were not signifant. Multiple nodules was the most common
type (33-43%), followed by single nodule (13-22%) and
direct spread from prirenal mass (11-28%). Diffise infil-
-
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Table IV Parameters influencing complete response rate
Complete No comrete
Total response response P-value
Total no. of patients 48 28 20
Renal localisation
Unique nodule 10 5 5
Multiple nodules 15 13 2
Diffuse infiltration 9 2 7
Penrenal mass 14 8 6 0.02
Renal hilum adenopathy
Yes 17 7 10
No 22 18 4
Unknown 9 0.02
Perinephric space infiltration
Yes 22 9 13
No 23 19 4
Unknown 3 0.01
Bilateral infiltration
Yes 21 15 6
No 27 13 14 NS
Lomboarotic adenopathies
Yes 33 19 14
No 15 9 6 NS
Creatinine level (pmol 1-)
>120 13 7 6
-120 35 21 14 NS
Histology
Diffuse large cell 29 21 8
Lymphoblastic 4 2 2
Others 15 5 10 NS
Age (years)
<55 21 14 7
.55 27 14 13 NS
tration was slightly more frequent (17%) in our study tha in
others (6%). Indeed, we included diffuse unilateral involve-
ment in the diffus infiltration, while other reports restricted
this type of involvement only to bilateral infiltration (Heiken
et al., 1983). Perirenal space was involved in 38-61% of
patients (Jafri et al., 1982; Heiken et al., 1983) and even more
(95%) in a histological study (Hartman et al., 1982). Lom-
boaortic lymph nodes were involved in 61-100% of patients
(Richards et al., 1990; Jafri et al., 1982; Heiken et al.,
1983).
Our study suggests an association between renal involve-
ment and mediastinum or bone involvement. These findings
have atready been reported (Perrone et al., 1986; Richards et
al., 1990).
Twenty-seven per cent of our patients, 25% of patients of
Richards et al. (1990) and six out of nine patients of Geffen
et al. (1985) had increased creatinine level (>120pmol 11).
We report three patients who presented with acute renal
failure (ARF). All of them had diffuse bilateral infiltration.
This association has been already described (Kanfer et al.,
1976; Randolph et al., 1983; Glicklich et al., 1986; Koolen et
al., 1988). The ACVB regimen is an intensive chemotherapy
regimen that includes no major nephrotoxic drugs, especially
no methotrexate, in the induction phase. Thus, we believe
that, based on our findings and the report of Geffen et al.
(1985), a patient with renal insufficiency caused by lym-
phomatous involvement of the kidneys could be treated
promptly with this combination chemotherapy in full dose.
Transient haemodialysis should eventually be useful.
Eighty-four per cent of the 48 patients received their first
chemotherapy cycle without dosage modification. Indeed,
initial impaired renal function rapidly improved with
chemotherapy. However, one patient with initial normal
renal function developed acute tumour lysis syndrome. This
metabolc disorder can occur in NHL patients with bulky
disease (Flombaum, 1988). Haematological toxicity in the 48
patients with renal involvement was similar to that in the 737
patients who received the LNH-84 protocol (Coiffier et al.,
1989). Furthermore, we found no influence of initial impair-
ment of renal function on haematological toxicity. We found
that treatment responses in kidneys and in other sites of
disease were similar and simultaneous. Radiological disap-
pearance was often rapid, within 1 week to 6 months (Ran-
dolph et al., 1983; Glicklich et al., 1986; Cadman et al., 1988;
Koolen et al., 1988; Richards et al., 1990).
Few series have described the results of treatment in
patients with aggressive lymphoma and renal involvement.
Complete remission has already been reported in primary
NHL (Betta et al., 1986) or in patients with acute renal
failure (Randolph et al., 1983; Koolen et al., 1988) with a
follow-up of more than 18 months. CR rate ranged from
44% to 69% in previous senres (Geffen et al., 1985; Richards
et al., 1990). CR persisted for more than 1 year in 38-54%
of patients (Geffen et al., 1985; Richards et al., 1990).
Relapse has occurred in 22-50% of CR patients (Geffen et
al., 1985; Richards et al., 1990). Twenty-three per cent of
patients died within 3-4 months after diagnosis, either from
disease progression or from toxicity of the induction regimen
(Geffen et al., 1985; Richards et al., 1990). The present report
describes the results of intensive combination chemotherapy
regimens in a large number of patients: The CR rate and the
percentage of patients who died during the induction phase
were estimated to be 57% and 27% respectively, and agree
with previous findings. Four year disease-free survival and 4
year overall survival were estimated to be 58 ± 9 and
46 ± 7% respectively.
Among initial renal characteristics, only diffuse infiltration
and hilus involvement had a poor prognostic value for sur-
vival in our series. In a previous report (Glicklich et al.,
1986), only one out of six patients with diffuse bilateral
involvement (and ARF) was alive at 2 years despite a
doxorubicin-containing regimen. However, multivariate
analysis demonstrated that no renal characteristics retained
independent prognostic value for survival. This analysis sug-AGGRESSIVE LYMPHOMAS WITH RENAL INVOLVEMENT 159
gests that only tumoral mass > 1Ocm (in kidney or
elsewhere) and performance status > 2 had independent
poor prognostic value for survival. Furthermore, we found a
large predominance of high-risk or high- to intermediate-risk
patients according to the prognostic index of the LNH-84
protocol or the international prognostic index. Ann Arbor
stage IV (Kanfer et al., 1976; Randolph et al., 1983; Geffen
et al., 1985; Glicklich et al., 1986; Richards et al., 1990) and
other extranodal localisation (Richards et al., 1990) were
nearly constant in previous reports, as in ours. Thus renal
involvement affected staging rarely. Geffen et al. (1985)
found at least one unfavourable prognostic factor in all
patients, and three or more unfavourable prognostic factors
in seven out of nine patients (Geffen et al., 1985). Finally,
our survival estimate agrees with that expected in a series of
patients with aggressive NHL and similar distribution of
prognostic index (Coiffier et al., 1991; Shipp et al., 1993).
In conclusion, renal involvement is rare and often asymp-
tomatic. Indeed, it usually occurs in the setting of
disseminated disease, with other unfavourable prognostic fac-
tors. Systemic chemotherapy improves renal function rapidly.
Responses to an intensive chemotherapy regimen are similar
to those obtained in other patients with advanced-stage NHL
with similar initial prognostic factors.
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